BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mulder TA, Peña-Pérez L, Berglöf A, Meinke S, Estupiñán HY, Heimersson K, Zain R, Månsson R, Smith CIE, Palma M. Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. Hemasphere 2021;5:e564. [PMID: 33912812 DOI: 10.1097/HS9.0000000000000564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cheng M, Yang F, Liu J, Yang D, Zhang S, Yu Y, Jiang S, Dong M. Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies. Front Cardiovasc Med 2021;8:758010. [PMID: 34869670 DOI: 10.3389/fcvm.2021.758010] [Reference Citation Analysis]
2 Zhu S, Jung J, Victor E, Arceo J, Gokhale S, Xie P. Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. Front Oncol 2021;11:737943. [PMID: 34778053 DOI: 10.3389/fonc.2021.737943] [Reference Citation Analysis]
3 Rivera D, Ferrajoli A. Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Curr Oncol Rep 2022. [PMID: 35366167 DOI: 10.1007/s11912-022-01261-9] [Reference Citation Analysis]
4 Zain R, Vihinen M. Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. Front Immunol 2021;12:694853. [PMID: 34349760 DOI: 10.3389/fimmu.2021.694853] [Reference Citation Analysis]
5 Broccoli A, Argnani L, Morigi A, Nanni L, Casadei B, Pellegrini C, Stefoni V, Zinzani PL. Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. J Clin Med 2021;10:5845. [PMID: 34945141 DOI: 10.3390/jcm10245845] [Reference Citation Analysis]
6 Palma M, Mulder TA, Österborg A. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Front Immunol 2021;12:686768. [PMID: 34276674 DOI: 10.3389/fimmu.2021.686768] [Reference Citation Analysis]
7 Blixt L, Bogdanovic G, Buggert M, Gao Y, Hober S, Healy K, Johansson H, Kjellander C, Mravinacova S, Muschiol S, Nilsson P, Palma M, Pin E, Smith CIE, Stromberg O, Sällberg Chen M, Zain R, Hansson L, Österborg A. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia 2021. [PMID: 34564699 DOI: 10.1038/s41375-021-01424-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]